NICE rejects Orchard’s gene therapy for rare childhood disease MLD
pharmaphorum
JULY 9, 2021
MLD is an inherited neurodegenerative disorder caused by a deficiency in the ARSA gene coding for the enzyme arylsulfatase-A, which allows sulphatide compounds to build up in the body. Orchard has already offered a confidential discount on the therapy.
Let's personalize your content